- Home
- IRIX vs EQ Comparison
IRIX vs EQ Comparison
Compare IRIX & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- EQ
- Stock Information
- Founded
- IRIX 1989
- EQ 2017
- Country
- IRIX United States
- EQ United States
- Employees
- IRIX N/A
- EQ N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- IRIX Health Care
- EQ Health Care
- Exchange
- IRIX Nasdaq
- EQ Nasdaq
- Market Cap
- IRIX 28.6M
- EQ 24.8M
- IPO Year
- IRIX 1996
- EQ 2018
- Fundamental
- Price
- IRIX $1.69
- EQ $0.63
- Analyst Decision
- IRIX Hold
- EQ Buy
- Analyst Count
- IRIX 1
- EQ 2
- Target Price
- IRIX $2.00
- EQ $5.00
- AVG Volume (30 Days)
- IRIX 46.3K
- EQ 130.9K
- Earning Date
- IRIX 11-12-2024
- EQ 11-13-2024
- Dividend Yield
- IRIX N/A
- EQ N/A
- EPS Growth
- IRIX N/A
- EQ N/A
- EPS
- IRIX N/A
- EQ N/A
- Revenue
- IRIX $48,431,000.00
- EQ $45,914,000.00
- Revenue This Year
- IRIX N/A
- EQ $4.76
- Revenue Next Year
- IRIX $5.44
- EQ N/A
- P/E Ratio
- IRIX N/A
- EQ N/A
- Revenue Growth
- IRIX N/A
- EQ 7.70
- 52 Week Low
- IRIX $1.27
- EQ $0.49
- 52 Week High
- IRIX $3.65
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- IRIX 49.97
- EQ 37.33
- Support Level
- IRIX $1.63
- EQ $0.49
- Resistance Level
- IRIX $1.67
- EQ $0.73
- Average True Range (ATR)
- IRIX 0.10
- EQ 0.08
- MACD
- IRIX -0.00
- EQ -0.01
- Stochastic Oscillator
- IRIX 37.93
- EQ 38.92
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.